Screener
Arbutus Biopharma Corporation ABUS Business Segments — Restructuring costs
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCharges.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| AB-101-001 clinical development expense | 526 | 1,899 |
| Other research and development expense | 2,703 | 4,889 |
| General and administrative expense | 5,889 | 5,832 |
| Restructuring expense | — | 12,373 |
| Other segment expense (1) | 237 | 323 |
| Add: | ||
| Interest income | 815 | 1,197 |
| Segment net income (loss) | $169,695 | $(24,526) |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's business segments — restructuring costs?
- Arbutus Biopharma Corporation (ABUS) reported business segments — restructuring costs of $0 in Q1 2026.
- How has Arbutus Biopharma Corporation's business segments — restructuring costs changed year-over-year?
- Arbutus Biopharma Corporation's business segments — restructuring costs decreased by 100.0% year-over-year, from $12.37M to $0.
- What does business segments — restructuring costs mean?
- These are non-recurring expenses related to organizational changes, such as workforce reductions, facility consolidations, or strategic pivots. High levels of these costs indicate significant operational transformation or efforts to improve long-term cost structures.
Ask your AI about Arbutus Biopharma Corporation's business segments — restructuring costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude